Bioanalytical Systems Inc (NASDAQ:BASI) files its latest 10-K with SEC for the fiscal year ended on September 30, 2017. Bioanalytical Systems Inc is a contract research organization providing drug discovery and development services and analytical instruments. Its customers and partners include pharmaceutical, biotechnology, academic and government organizations. Bioanalytical Systems Inc has a market cap of $22.010 million; its shares were traded at around $2.64 with a P/E ratio of 23.98 and P/S ratio of 0.96.
For the last quarter Bioanalytical Systems Inc reported a revenue of $5.87 million, compared with the revenue of $5.15 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $24.2 million, an increase of 18.6% from last year. For the last five years Bioanalytical Systems Inc had an average revenue decline of 3% a year.
The reported diluted earnings per share was 10 cents for the year, an increase of -125% from previous year. The Bioanalytical Systems Inc had an operating margin of 5.27%, compared with the operating margin of -14.87% a year before. The 10-year historical median operating margin of Bioanalytical Systems Inc is 2.56%. The profitability rank of the company is 4 (out of 10).
Top 10 Biotech Stocks To Watch Right Now: Amgen Inc.(AMGN)
Advisors' Opinion:- [By Keith Speights]
Amgen (NASDAQ:AMGN) has been the hands-down winner over Celgene (NASDAQ:CELG) in terms of stock performance over the last year. It's the same story for revenue generated. Celgene beat Amgen in earnings, but only because of a technicality: Amgen incurred a big one-time tax hit in 2017.
- [By Shane Hupp]
Amgen (NASDAQ:AMGN)‘s stock had its “buy” rating reissued by Oppenheimer in a research note issued on Tuesday. They currently have a $224.00 price objective on the medical research company’s stock. Oppenheimer’s price target would indicate a potential upside of 8.26% from the stock’s current price.
- [By Max Byerly]
Hammer Asset Management LLC purchased a new stake in Amgen, Inc. (NASDAQ:AMGN) during the second quarter, according to its most recent 13F filing with the SEC. The firm purchased 16,988 shares of the medical research company’s stock, valued at approximately $3,136,000. Amgen makes up 2.7% of Hammer Asset Management LLC’s holdings, making the stock its 13th largest holding.
- [By ]
Booker's report took on other companies as well. Pfizer (PFE) , Gilead Sciences (GILD) , AbbVie (ABBV) , Amgen (AMGN) , Bristol-Myers Squibb (BMY) Eli Lilly & Co. (LLY) , and Mylan NV (MYL) are cited for everything from raising drug prices, to stock buybacks and putting shareholder interest before that of the public.
Top 10 Biotech Stocks To Watch Right Now: ArQule Inc.(ARQL)
Advisors' Opinion:- [By Max Byerly]
Get a free copy of the Zacks research report on ArQule (ARQL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Stephan Byrd]
Get a free copy of the Zacks research report on ArQule (ARQL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Joseph Griffin]
Shares of ArQule, Inc. (NASDAQ:ARQL) were down 5.4% during trading on Wednesday . The company traded as low as $4.71 and last traded at $4.73. Approximately 3,358,864 shares traded hands during trading, an increase of 289% from the average daily volume of 863,008 shares. The stock had previously closed at $5.00.
- [By Cory Renauer]
What's behind these dramatic gains? Read on to find out.
Company Gain in H1 2018 Market Cap Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) 270% $1.19 billion ArQule, Inc. (NASDAQ:ARQL) 235% $482 million Endocyte, Inc. (NASDAQ:ECYT) 222% $959 million Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) 205% $3.99 billionData source: YCharts.
- [By Logan Wallace]
BidaskClub upgraded shares of ArQule (NASDAQ:ARQL) from a hold rating to a buy rating in a report released on Saturday.
A number of other research firms have also issued reports on ARQL. Roth Capital upped their price target on ArQule from $5.00 to $6.00 and gave the company a buy rating in a research report on Tuesday, April 17th. Leerink Swann upgraded ArQule from a market perform rating to an outperform rating in a research report on Thursday, April 5th. Zacks Investment Research lowered ArQule from a buy rating to a hold rating in a research report on Wednesday, April 4th. ValuEngine upgraded ArQule from a hold rating to a buy rating in a research report on Wednesday, May 2nd. Finally, B. Riley set a $4.00 price target on ArQule and gave the company a buy rating in a research report on Monday, March 26th. Seven analysts have rated the stock with a buy rating, The stock currently has an average rating of Buy and an average target price of $4.69.
- [By Maxx Chatsko]
Shares of development-stage biopharma ArQule (NASDAQ:ARQL) rose nearly 17% today after the company announced two appointments to its management team in two newly created positions. Dr. Marc Schegerin will serve as senior vice president, corporate strategy, communication, and finance. Dr. Shirish Hirani will serve as senior vice president, program management and product planning.
Top 10 Biotech Stocks To Watch Right Now: Alnylam Pharmaceuticals Inc.(ALNY)
Advisors' Opinion:- [By Motley Fool Staff]
Alnylam's (NASDAQ:ALNY) Onpattro is the first Food and Drug Administration (FDA)-approved RNAi therapy. However, competition is fast approaching and could make it difficult for Alnylam to pocket profits. Can Onpattro carve out significant sales as a treatment for polyneuropathy in hereditary transthyretin-mediated (hATTR) amyloidosis?
- [By Jim Crumly]
As for individual stocks, shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) fell despite the announcement of its first-ever drug approval, and those of Sysco (NYSE:SYY) rose on earnings.
- [By Shane Hupp]
Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Logan Wallace]
Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Although Alnylam has a broad and promising pipeline, we note that most candidates are in mid stages of development. These candidates still have a long way to go before hitting the market. The company relies highly on collaborators for funding. Any development/regulatory setback would be a negative for the company. However, Alnylam reported positive data from the ATLAS study in the first quarter which led to regulatory filings for its late-stage pipeline candidate patisiran and the FDA set an action date of Aug 11, 2018. The company along with its partners Sanofi and The Medicines Company, restarted fitusiran's ATLAS phase III study and advanced inclisiran in the ORION-9, -10, and -11 phase III studies, respectively, with results expected for both programs in 2019. Alnylam expects to achieve the profile of three marketed products by the end of 2020.”
- [By Brian Orelli]
Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) were up 19% at 12:04 p.m. EDT on Monday after rival Pfizer (NYSE:PFE) released data for its transthyretin amyloid (ATTR) drug tafamidis at the ESC Congress 2018, which were also published in the New England Journal of Medicine. Earlier this month, Alnylam got its ATTR drug, Onpattro, approved by the Food and Drug Administration. Shares of Ionis Pharmaceuticals (NASDAQ:IONS) and Akcea Therapeutics (NASDAQ:AKCA), which are jointly developing another ATTR drug, Tegsedi, are up 10% and 2.6% respectively.
- [By Shane Hupp]
Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Although we are pleased with Alnylam’s broad and promising pipeline, we note that most candidates are in their early or mid stages of development. These candidates still have a long way to go before hitting the market. Currently, Alnylam depends heavily on Onpattro for growth. We also note that gaining approval for pipeline candidates has become more difficult now. However, In August, Alnylam got a significant boost with the approval of Onpattro (patisiran), a first-of-its-kind RNA interference (RNAi) therapeutic, both in the United States and in Europe, for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. This is the first approved candidate for the company and hence should drive revenues. Loss estimates have remained stable ahead of the Q3 earnings release.”
Top 10 Biotech Stocks To Watch Right Now: Biogen Idec Inc(BIIB)
Advisors' Opinion:- [By Chris Lange]
The S&P 500 stock posting the largest daily percentage loss ahead of the close was Biogen Inc. (NASDAQ: BIIB) which traded down over 5% at $288.75. The stock's 52-week range is $249.17 to $370.57. Volume was 3.2 million compared to the daily average volume of 1.7 million.
- [By Sean Williams, Chuck Saletta, and Brian Feroldi]
As noted, the ability to take numerous swings for the fence makes Ionis special. It's often a marvel when a mid-cap drugmaker has a half-dozen experimental drugs, let alone one working with 25. Spinal muscular atrophy drug Spinraza, which was licensed to Biogen (NASDAQ:BIIB), is one such drug that's put Ionis and its antisense technology on the map. Last year, Spinraza netted "just" $882 million in total sales, but delivered $364 million globally in the first quarter of 2018. That extrapolates out to more than $1.4 billion, which means added royalty revenue for Ionis.
- [By Keith Speights]
Shares of Biogen Inc. (NASDAQ:BIIB) were up 15.2% as of 11:35 a.m. EDT on Friday after the biotech, along with partner Eisai, reported encouraging results from a phase 2 clinical study of BAN2401 in treating Alzheimer's disease. Patients taking BAN2401 achieved statistically significant improvement compared to patients on placebo after 18 months in slowing progression of Alzheimer's disease and in the reduction of amyloid accumulations in the brain.
- [By Jim Crumly]
As for individual stocks, Biogen (NASDAQ:BIIB) made headlines with positive results from a trial of an Alzheimer's drug, and PriceSmart (NASDAQ:PSMT) fell after reporting earnings.
- [By Brian Orelli]
Drug-developer Biogen (NASDAQ:BIIB) reported a pretty strong earnings increase in the first quarter. While revenue growth wasn't as solid, investors appear to be giving management a pass, thanks to its explanations on why slowing first-quarter sales aren't a sign of future trouble.
- [By Garrett Baldwin] Shares of Ford Motor Co. (NYSE: F) were flat despite dismal news out of China. This morning, the company reported a 38% slump in Chinese sales during the month of June. It was a terrible first six months for the iconic vehicle manufacturer. The company said that its Chinese operations saw a 25% slide in sales over the first half of the year. That was the largest six-month decline since launching its Chinese operations in 2001. Shares of Tesla Inc. (Nasdaq: TSLA) are off more than 1% after California regulators announced a new probe into the company. The probe was announced following a safety complaint filed with the Occupational Safety and Health Administration. The agency has not provided any details on the case. Shares of Biogen Inc. (Nasdaq: BIIB) popped more than 14% after the company announced positive results from a trial for an Alzheimer's drug. The phase 2 study examined BAN2401, an anti-amyloid beta protofibril antibody. It was tested on 856 patients with early stages of Alzheimer's disease. In a research note, JPMorgan Chase & Co. (NYSE: JPM) announced that the results would be positive for Biogen's drug pipeline. Look for an earnings report Friday from InnerWorkings Inc. (Nasdaq: INWK). Wall Street projects that the company will report earnings per share of $0.09 on top of $284.9 million in revenue.
Follow Money Morning on Facebook, Twitter, and LinkedIn.
No comments:
Post a Comment